

Supplementary table 4. Statistical analysis about the risk of gallbladder disease in relation to age

| MHT | GB disease (GB stone + cholecystitis) ^a | |
|------------------------------------------------------|----------------------------------------------------|---------|
| | HR (95% CI) ^a | P-value |
| 50~59 years | | |
| Tibolone | 1.26 (1.202-1.321) | <0.001 |
| Combined Estrogen plus progestin by the manufacturer | 1.123 (1.055-1.196) | <0.001 |
| Estrogen | 1.134 (1.033-1.245) | 0.008 |
| Combined Estrogen plus progestin by the physician | 1.188 (0.955-1.477) | 0.122 |
| Topical estrogen | 1.473 (1.022-2.121) | 0.038 |
| 60~69 years | | |
| Tibolone | 1.065 (0.956-1.186) | 0.251 |
| Combined Estrogen plus progestin by the manufacturer | 0.887 (0.737-1.067) | 0.204 |
| Estrogen | 1.236 (1.051-1.454) | 0.011 |
| Combined Estrogen plus progestin by the physician | 0.817 (0.5-1.335) | 0.419 |
| Topical estrogen | 0.7 (0.225-2.171) | 0.536 |
| 70 years~ | | |
| Tibolone | 1.162 (0.874-1.544) | 0.301 |
| Combined Estrogen plus progestin by the manufacturer | 1.339 (0.791-2.268) | 0.278 |
| Estrogen | 1.085 (0.718-1.638) | 0.699 |
| Combined Estrogen plus progestin by the physician | 0 (0-1.181E+94) | 0.931 |
| Topical estrogen | 0 (0-3.55E+171) | 0.961 |

CI, confidence interval; HR, hazard ratio

^a HRs were adjusted for body mass index, socioeconomic status, region, Charlson comorbidity index, parity, age at menarche, age at menopause, smoking, alcohol, physical exercise, gallbladder disease, hypertension, diabetes mellitus, stroke, period from menopause to inclusion.